Halyard Health, Inc. (NYSE:HYH) was upgraded by ValuEngine from a “hold” rating to a “buy” rating in a report issued on Saturday.

A number of other brokerages have also recently issued reports on HYH. Stifel Nicolaus reiterated a “buy” rating and set a $52.00 price objective on shares of Halyard Health in a research note on Friday. BidaskClub cut Halyard Health from a “buy” rating to a “hold” rating in a research note on Saturday, July 8th. Zacks Investment Research cut Halyard Health from a “hold” rating to a “sell” rating in a research note on Tuesday, October 10th. KeyCorp reiterated a “hold” rating on shares of Halyard Health in a research note on Tuesday, October 17th. Finally, Stephens upgraded Halyard Health from an “equal weight” rating to an “overweight” rating in a research note on Thursday, August 3rd. Three equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $44.00.

Halyard Health (NYSE HYH) opened at $47.33 on Friday. The company has a market cap of $2.20 billion, a P/E ratio of 22.49, a P/E/G ratio of 3.14 and a beta of 1.69. The company has a debt-to-equity ratio of 0.49, a current ratio of 2.13 and a quick ratio of 1.11.

Halyard Health (NYSE:HYH) last released its earnings results on Wednesday, November 1st. The medical instruments supplier reported $0.60 EPS for the quarter, beating the Zacks’ consensus estimate of $0.47 by $0.13. The company had revenue of $401.40 million during the quarter, compared to analysts’ expectations of $394.54 million. Halyard Health had a return on equity of 8.65% and a net margin of 3.52%. The firm’s revenue for the quarter was up 1.0% compared to the same quarter last year. During the same quarter last year, the business posted $0.48 EPS. analysts forecast that Halyard Health will post 2.08 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This story was originally reported by Watch List News and is the property of of Watch List News. If you are viewing this story on another domain, it was illegally copied and republished in violation of United States and international copyright & trademark law. The legal version of this story can be accessed at https://www.watchlistnews.com/halyard-health-inc-hyh-upgraded-to-buy-by-valuengine/1676900.html.

A number of large investors have recently made changes to their positions in HYH. UBS Asset Management Americas Inc. raised its stake in Halyard Health by 11.3% during the first quarter. UBS Asset Management Americas Inc. now owns 34,269 shares of the medical instruments supplier’s stock valued at $1,305,000 after buying an additional 3,473 shares during the last quarter. Principal Financial Group Inc. raised its stake in shares of Halyard Health by 2.2% in the first quarter. Principal Financial Group Inc. now owns 193,168 shares of the medical instruments supplier’s stock worth $7,358,000 after purchasing an additional 4,141 shares during the last quarter. Teachers Advisors LLC raised its stake in shares of Halyard Health by 1.5% in the first quarter. Teachers Advisors LLC now owns 83,319 shares of the medical instruments supplier’s stock worth $3,174,000 after purchasing an additional 1,249 shares during the last quarter. Legal & General Group Plc raised its stake in shares of Halyard Health by 5.6% in the first quarter. Legal & General Group Plc now owns 64,921 shares of the medical instruments supplier’s stock worth $2,473,000 after purchasing an additional 3,415 shares during the last quarter. Finally, Thrivent Financial For Lutherans raised its stake in shares of Halyard Health by 10.2% in the first quarter. Thrivent Financial For Lutherans now owns 8,847 shares of the medical instruments supplier’s stock worth $337,000 after purchasing an additional 820 shares during the last quarter. Institutional investors and hedge funds own 91.03% of the company’s stock.

About Halyard Health

Halyard Health, Inc is a medical technology company. The Company operates through two segments: Medical Devices and Surgical and Infection Prevention (S&IP). The Medical Devices segment provides a portfolio of product offerings focused on pain management, respiratory and digestive health. The S&IP segment provides healthcare supplies and solutions that target the prevention of healthcare-associated infections.

Analyst Recommendations for Halyard Health (NYSE:HYH)

Receive News & Ratings for Halyard Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halyard Health Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.